Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

HudsonAlpha Institute's HOPE-AD study offers Alzheimer's risk assessment, revealing proactive steps high-risk individuals can ...

The real drug development delay? Bad communication.

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.